Head-To-Head Analysis: Semler Scientific (NASDAQ:SMLR) versus CardioGenics (OTCMKTS:CGNH)

CardioGenics (OTCMKTS:CGNH) and Semler Scientific (NASDAQ:SMLR) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, profitability, risk and valuation.

Institutional & Insider Ownership

49.4% of Semler Scientific shares are held by institutional investors. 41.4% of CardioGenics shares are held by company insiders. Comparatively, 16.4% of Semler Scientific shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and target prices for CardioGenics and Semler Scientific, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CardioGenics	0	0	0	0	0.00
Semler Scientific	0	1	4	0	2.80

Semler Scientific has a consensus price target of $74.25, indicating a potential upside of 265.22%. Given Semler Scientific’s stronger consensus rating and higher possible upside, analysts plainly believe Semler Scientific is more favorable than CardioGenics.

Risk and Volatility

CardioGenics has a beta of 2.44, meaning that its stock price is 144% more volatile than the S&P 500. Comparatively, Semler Scientific has a beta of 1.35, meaning that its stock price is 35% more volatile than the S&P 500.

Valuation & Earnings

This table compares CardioGenics and Semler Scientific”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CardioGenics	N/A	N/A	N/A	N/A	N/A
Semler Scientific	$56.29 million	5.48	$40.90 million	$2.78	7.31

Semler Scientific has higher revenue and earnings than CardioGenics.

Profitability

This table compares CardioGenics and Semler Scientific’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CardioGenics	N/A	N/A	N/A
Semler Scientific	130.80%	34.21%	25.58%

Summary

Semler Scientific beats CardioGenics on 8 of the 10 factors compared between the two stocks.

About CardioGenics

CardioGenics Holdings Inc. engages in the development and commercialization of diagnostic test products for the in vitro diagnostics testing market in the United States, Canada, Europe, and internationally. Its products include QL Care Analyzer, a portable, stand-alone, and automated point-of-care (POC) immunoassay analyzer that uses a proprietary self-metering cartridge to perform immunoassay tests at the POC; a series of immunoassay tests to identify cardiac markers in the blood at the time of a heart attack; and paramagnetic beads that are used as solid surfaces in heterogeneous immunoassay tests by clinical and research laboratories. The company was formerly known as Jag Media Holdings, Inc. and changed its name to CardioGenics Holdings Inc. in 2009. The company was founded in 1997 and is headquartered in Mississauga, Canada.

About Semler Scientific

Semler Scientific, Inc. provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company’s products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient’s vascular condition. It also offers Insulin Insights, a software program that is used by a healthcare provider to optimize outpatient insulin dosing. The company’s products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, family practitioners, healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups and retailers. It offers its products through sales representatives and distributors. The company was incorporated in 2007 and is headquartered in Santa Clara, California.